As of Aug 27
| +0.21 / +2.77%|
The 1 analysts offering 12-month price forecasts for SciClone Pharmaceuticals Inc have a median target of 7.50, with a high estimate of 7.50 and a low estimate of 7.50. The median estimate represents a -3.60% decrease from the last price of 7.78.
The current consensus among 1 polled investment analysts is to Sell stock in SciClone Pharmaceuticals Inc. This rating has held steady since August, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.